These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 11848489)

  • 1. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone.
    Gokhale PC; Pei J; Zhang C; Ahmad I; Rahman A; Kasid U
    Anticancer Res; 2001; 21(5):3313-21. PubMed ID: 11848489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Separation of liposome-entrapped mitoxantrone from nonliposomal mitoxantrone in plasma: pharmacokinetics in mice.
    Ahmad A; Wang YF; Ahmad I
    Methods Enzymol; 2005; 391():176-85. PubMed ID: 15721381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice].
    Chen T; Hou SX; Wang YY; Zhang WS; Chen DH
    Yao Xue Xue Bao; 2006 Dec; 41(12):1170-5. PubMed ID: 17290615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome.
    Gokhale PC; Zhang C; Newsome JT; Pei J; Ahmad I; Rahman A; Dritschilo A; Kasid UN
    Clin Cancer Res; 2002 Nov; 8(11):3611-21. PubMed ID: 12429653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy.
    Li C; Cui J; Wang C; Li Y; Zhang H; Wang J; Li Y; Zhang L; Zhang L; Guo W; Wang Y
    Eur J Pharm Biopharm; 2008 Oct; 70(2):657-65. PubMed ID: 18582570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone.
    Lim HJ; Masin D; Madden TD; Bally MB
    J Pharmacol Exp Ther; 1997 Apr; 281(1):566-73. PubMed ID: 9103545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone-loaded BSA nanospheres and chitosan nanospheres for local injection against breast cancer and its lymph node metastases. II: Tissue distribution and pharmacodynamics.
    Lu B; Xiong SB; Yang H; Yin XD; Zhao RB
    Int J Pharm; 2006 Jan; 307(2):175-81. PubMed ID: 16314056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacodynamics, pharmacokinetics and tissue distribution of liposomal mitoxantrone hydrochloride].
    Wang CX; Li CL; Zhao X; Yang HY; Wei N; Li YH; Zhang L; Zhang L
    Yao Xue Xue Bao; 2010 Dec; 45(12):1565-9. PubMed ID: 21351498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy.
    Schwendener RA; Fiebig HH; Berger MR; Berger DP
    Cancer Chemother Pharmacol; 1991; 27(6):429-39. PubMed ID: 2013113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma membrane targeting by short chain sphingolipids inserted in liposomes improves anti-tumor activity of mitoxantrone in an orthotopic breast carcinoma xenograft model.
    Cordeiro Pedrosa LR; van Tellingen O; Soullié T; Seynhaeve AL; Eggermont AM; Ten Hagen TL; Verheij M; Koning GA
    Eur J Pharm Biopharm; 2015 Aug; 94():207-19. PubMed ID: 25982691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases.
    Lu B; Xiong SB; Yang H; Yin XD; Chao RB
    Eur J Pharm Sci; 2006 May; 28(1-2):86-95. PubMed ID: 16472996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.
    Lim HJ; Masin D; McIntosh NL; Madden TD; Bally MB
    J Pharmacol Exp Ther; 2000 Jan; 292(1):337-45. PubMed ID: 10604968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated liposomal mitoxantrone is more therapeutically active than mitoxantrone in L1210 ascitic tumor and exhibits dose-dependent activity saturation effect.
    Li C; Zhao X; Deng C; Wang C; Wei N; Cui J
    Int J Pharm; 2014 Jan; 460(1-2):165-72. PubMed ID: 24148664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models.
    Tardi P; Choice E; Masin D; Redelmeier T; Bally M; Madden TD
    Cancer Res; 2000 Jul; 60(13):3389-93. PubMed ID: 10910044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal mitoxantrone for the local treatment of peritoneal carcinomatosis induced by colon cancer cells in mice.
    Genne P; Olsson NO; Gutierrez G; Duchamp O; Chauffert B
    Anticancer Drug Des; 1994 Apr; 9(2):73-84. PubMed ID: 8166930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine.
    Allen TM; Mehra T; Hansen C; Chin YC
    Cancer Res; 1992 May; 52(9):2431-9. PubMed ID: 1568213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice.
    Desjardins J; Emerson DL; Colagiovanni DB; Abbott E; Brown EN; Drolet DW
    J Pharmacol Exp Ther; 2004 Jun; 309(3):894-902. PubMed ID: 14982966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.
    Emerson DL; Bendele R; Brown E; Chiang S; Desjardins JP; Dihel LC; Gill SC; Hamilton M; LeRay JD; Moon-McDermott L; Moynihan K; Richardson FC; Tomkinson B; Luzzio MJ; Baccanari D
    Clin Cancer Res; 2000 Jul; 6(7):2903-12. PubMed ID: 10914740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents.
    Patel JB; Khandelwal A; Chopra P; Handratta VD; Njar VC
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):899-905. PubMed ID: 17345084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation.
    Gokhale PC; Radhakrishnan B; Husain SR; Abernethy DR; Sacher R; Dritschilo A; Rahman A
    Br J Cancer; 1996 Jul; 74(1):43-8. PubMed ID: 8679456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.